Research progress on predictors of interferon treatment in patients with chronic hepatitis B
Interferon-alpha (IFN-α) remains as one of the first-line drugs used in chronic hepatitis B treatment. IFN-α has several advantages, such as finite course of therapy and long-term benefit. However, clinical application of IFN-α is still limited due to its side effect and inefficient antiviral ability. Therefore, it is very important for physicians to learn how to predict the efficacy of IFN-α treatment in patients with chronic hepatitis B. In this review, we focus on some various factors which can affect the efficacy of IFN-α treatment, hoping can provide reference for the clinicians.